On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers associated with Alzheimer's pathology, including p-tau 217, as well as cognitive and functional measures in approximately 400 participants over 52 weeks. This development expands the company's clinical program for obicetrapib alongside ongoing Phase 3 trials for cardiovascular indications. NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company developing oral, non-statin medicines to lower LDL cholesterol and treat cardiometabolic and neurodegenerative diseases.
